Author

F. Giancotti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. K. Ghosh· 1 shared A. T. Raman· 1 shared C. J. Logothetis· 1 shared C. Terranova· 1 shared E. Caggiano· 1 shared E. Orouji· 1 shared H. Chen· 1 shared H.-H. Ling· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. K. Ghosh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

C. Terranova, M. Maitituoheti, A. T. Raman, M. Tang, N. E. Anvar, A. K. Ghosh, S. B. Amin, J. Schulz, E. Orouji, F. Giancotti, P. Troncoso, C. J. Logothetis, T. Thompson, K. Rai

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology

SARS-CoV-2 Exploits Sexually Dimorphic and Adaptive IFN and TNFa Signaling to Gain Entry into Alveolar Epithelium

F. Giancotti, Y. Wang, S. Gurrapu, H. Chen, S. Laudato, E. Caggiano, Y. Jiang, H.-H. Ling

This study shows SARS-CoV-2 exploits sex-specific IFN and TNFα signaling to enhance ACE2 and TMPRSS2 expression in male alveolar cells, promoting viral entry and suggesting potential therapeutic targets.

bioRxiv · Jul 23, 2021 · PreprintImmunology